Third Quarter 2024 Financial Results Cash, cash equivalents, and investments as of September 30, 2024, were approximately $19.7 million. The Company anticipates that its cash, cash equivalents and ...
The company has discontinued the Phase I/II trial of its only clinical candidate due to a potential “unfavourable ...
One of three people involved in a drug investigation dating back to last year has been sentenced to nine years.
Achieves Robust Financial Performance with 74% Gross Margin and Strategic Public Offering, Bolstering Resources for Continued Growth and Innovation.Elevai Enfinity Clinical Trials Showcase Breakthroug ...
The new rules, which cover both TV and radio, instruct drugmakers to use simple, consumer-friendly language when describing ...
AZoLifeSciences on MSN4h
The Commercialization Process for Antibody TherapeuticsThe rise of antibody therapeutics is transforming drug discovery, providing highly specific treatments for complex diseases ...
For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...
Robert W. Baird analyst Brian Skorney maintained a Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report) on November 12 and ...
Analyst Michael Ulz from Morgan Stanley reiterated a Buy rating on Dyne Therapeutics (DYN – Research Report) and keeping the price target ...
The novel oral first-in-class anti-inflammatory agent has demonstrated robust efficacy and high safety margins in preclinical studies, and is the first drug candidate to advance to clinical trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback